Growth in clinical research capability in China and impact on the pharmaceutical sector nature.com/articles/d41... This new article analyses data on the growth in inputs to clinical research capability in China and its impact on outputs such as investigator-initiated trials

For readers interested in mRNA therapeutics, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies, here's a comprehensive review nature.com/articles/s41... rdcu.be/friiI

The history and future of cancer immunotherapy is being discussed at a panel at #BIO2026 , and agonistic antbody immunotherapies have been highlighted - here's a comprehensive review on realizing their potential www.nature.com/articles/s41... rdcu.be/fqohC

Time to peak sales: how long is the climb? www.nature.com/articles/d41... This new article analyses trends in the time to peak sales for drugs launched in the past two decades and the underlying drivers

The PI3K/AKT/mTOR pathway has been a popular therapeutic target for cancer, immune regulation and genetic disorders. This Perspective in the June issue discusses challenges, lessons learned and new efforts in targeting this pathway www.nature.com/articles/s41... rdcu.be/fqcwb

This Nature conference will bring together researchers from academia and industry to explore the evolving landscape of cancer therapeutics. Join us in Houston this October for discussions on next‑generation therapies and emerging approaches. go.nature.com/4daqpHm

Multispecific T-cell engagers attract cancer drug developers nature.com/articles/d41... Multispecific T-cell engagers that bind three or more targets on cancer and immune cells promise to address the shortcomings of their bispecific predecessors

Can multispecific biologics break the efficacy ceiling? nature.com/articles/d41... A growing pipeline of multispecific antibody therapies are in clinical trials, showcasing novel biological effects as well as potential improvements over multi-agent cocktails

Wearable technologies are increasingly being integrated into clinical trials. This Review in the June issue covers this evolving landscape, including the technologies and the translational pathways for wearable-derived measures in drug development www.nature.com/articles/s41... rdcu.be/foTjR

For readers interested in inhibitors of the JAK-STAT pathway as drugs for immunological and haematological diseases, here's a recent comprehensive review www.nature.com/articles/s41... rdcu.be/foHob

The unglamourous AI wins that are quietly transforming drug discovery and development nature.com/articles/d41... David Reese, Amgen’s inaugural Chief Technology Officer, discusses how inconspicuous AI achievements stand to transform drug discovery

Novel drug targets in 2025 www.nature.com/articles/d41... This new article highlights 11 targets not previously modulated by approved drugs

Antiviral peptide nabs FDA approval for hepatitis delta virus infection www.nature.com/articles/d41... Gilead’s bulevirtide is the first treatment for the potentially fatal infection

Evolution of the psoriasis therapy landscape www.nature.com/articles/d41... This new article analyses the pipeline of drugs for psoriasis and their market impact, highlighting the growing importance of oral therapies

For readers interested in next-generation GLP-1-based therapies for diabetes, obesity and more, here's a review nature.com/articles/s41... rdcu.be/fnl3W

AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments. www.statnews.com/2026/06/08/a...

A guide to effective drug development through nonprofit models www.nature.com/articles/d41... Patient organizations are reshaping rare disease drug development. Based on a survey, interviews and experience, this article discusses how to direct resources toward drug development goals

Our June issue is live! Read about the therapeutic potential of orphan GPCRs, wearable technologies in clinical trials for drug development, a renaissance in targeting the PI3K/AKT/mTOR pathway and more here www.nature.com/nrd/volumes/...

Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus www.nature.com/articles/d41... This new article argues that the ongoing Ebola outbreak should be a turning point for moving R&D towards species-inclusive and broadly applicable filovirus countermeasures

Better data for better medicines: a path to data-driven medicines regulation www.nature.com/articles/d41... This new Comment article highlights how the EU medicines regulatory system is becoming more data-driven

Towards mRNA therapeutics 2.0 www.nature.com/articles/s41... This new Review discusses progress and insights from clinical studies on mRNA-based drugs, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies

For readers interested in kinase inhibitors in cancer and beyond, this Review covers the expanding toolkit for kinase modulation, including allosteric modulators and proximity-inducing molecules such as molecular glues www.nature.com/articles/s41... rdcu.be/fl5H5 #ASCO26

For readers interested in cancer immunotherapy, this article reviews the clinical landscape for agonistic antibodies as immunotherapies and discusses how mechanistic insights should broaden their clinical application www.nature.com/articles/s41... rdcu.be/flSve #ASCO26

For readers interested in cyclin-dependent kinase inhibitors in cancer, here's a comprehensive review discussing their progression beyond CDK4/6 inhibitors for breast cancer nature.com/articles/s41... rdcu.be/flRPL #ASCO26

Targeting claudins in cancer www.nature.com/articles/s41... rdcu.be/flf2S Claudins, which are key regulators of epithelial function, are emerging as targets in cancer, validated by the approval of a CLDN18.2-targeted drug. This new Review discusses progress in the field #ASCO26

This Review in the May issue discusses how microglia integrate signals from central and peripheral immune cells in neurodegenerative disorders, highlighting therapeutic targets and biomarkers www.nature.com/articles/s41... rdcu.be/fk3uL

Antibody-based extracellular targeted protein degraders that destroy disease-linked proteins in cancer and autoimmunity are advancing in the clinic. Find out more in this news story in our May issue www.nature.com/articles/d41...

Review @natrevdrugdiscov.nature.com Realizing the potential of agonistic antibody immunotherapy www.nature.com/articles/s41...

For readers interested in the evolution of obesity therapy from GLP-1 receptor agonists to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting, here's a comprehensive new Review nature.com/articles/s41...

Our latest research highlight covers a paper in Nature on a quintuple agonist of GLP-1R, GIPR and PPARα/γ/δ that outperforms GLP-1R agonism in obese mice nature.com/articles/d41...

Twenty years of induced pluripotent stem cells www.nature.com/articles/d41... Nobel laureate Shinya Yamanaka discusses the therapeutic and drug discovery applications for induced pluripotent stem cells in this new interview

FDA approves first-in-class hypertension drug www.nature.com/articles/d41... AstraZeneca’s baxdrostat is the first aldosterone synthase inhibitor to be approved, providing a new way to lower blood pressure. Peak sales >$5 billion are forecasted, but two competitors are close behind

Extrachromosomal DNA (ecDNA) drives oncogene amplification, tumour evolution and drug resistance across cancers. This Review in the May issue discusses the translation of ecDNA-targeted therapeutic approaches from bench to bedside www.nature.com/articles/s41... rdcu.be/fjMqd

Realizing the potential of agonistic antibody immunotherapy www.nature.com/articles/s41... rdcu.be/fjzZk This new Review discusses progress with agonist antibodies to treat autoimmune diseases and cancer, as well as approaches to addressing challenges in their development

Registration and abstract submissions are now open for Next Generation Cancer Therapeutics. This Nature Conference will bring together leading global researchers who are transforming the landscape of cancer therapies for discussions and networking. go.nature.com/4eHSlnc #STEMConference

Autophagy modulation in cancer www.nature.com/articles/s41... rdcu.be/fjmxZ This new Review discusses the promise and limitations of targeting autophagy to limit malignant transformation, exacerbate cancer cell death driven by conventional drugs and restore immunosurveillance

Trends in the landscape of clinical trials of innovative drugs in China since 2015 www.nature.com/articles/d41... This analysis highlights how China has become a high-volume destination for clinical trials in the past decade, driven by regulatory modernization and capital investment

A new article in Nature Reviews Drug Discovery, inspired by discussions at previous International Drug Repurposing Conferences (iDR), explores how we can make the most of the potential of drug repurposing. 🔗 Read the article: https://bit.ly/4eyNFjq 🎟️ Register for iDR26: remedi4all.org/iDR26

The evolving landscape of obesity pharmacotherapy www.nature.com/articles/s41... rdcu.be/fiw7g This new Review covers the evolution of obesity pharmacotherapy from GLP1 receptor agonists to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting

Blood–brain barrier (BBB) dysfunction is a hallmark of many diseases of the brain, such as Alzheimer disease. This Review in the May issue covers strategies for BBB repair and protection in various diseases and during normal ageing rdcu.be/fij4F www.nature.com/articles/s41...

The ovarian cancer drug market www.nature.com/articles/d41... This new article analyses the pipeline of drugs in development for ovarian cancer, such as antibody-drug conjugates, and their expected impact on the market

First PROTAC gains FDA approval, bolstering targeted protein degradation and induced proximity ambitions www.nature.com/articles/d41...

Our May issue is live! Read about biologic targeted protein degraders, strategies for blood-brain barrier rejuvenation and repair, targeting extrachromosomal DNA in cancer, therapeutic targeting of neuroimmune mechanisms in neurodegeneration and more here nature.com/nrd/volumes/...

For readers interested in drug repurposing, this Review evaluates computational approaches to drug repurposing based on categorization of available resources into an online catalogue www.nature.com/articles/s41... rdcu.be/fhe2Z

Bridging boundaries: making drug repurposing the new normal nature.com/articles/d41... This new article discusses approaches to overcoming systemic challenges in drug repurposing, enabling the approach to contribute more to new therapies, especially for rare diseases

Shifts in pharma’s therapeutic area focus www.nature.com/articles/d41... This new article analyses the evolution of the therapeutic area focus of large pharmaceutical companies, as well as phase III resourcing and the composition of drug launches

Sarah Crunkhorn, Senior Editor at Nature Reviews Drug Discovery, will be attending the TIDES conference on oligonucleotide and peptide therapeutics in Boston on 11-14 May informaconnect.com/tides/ #TIDESUSA

The landscape for therapeutic cancer vaccines www.nature.com/articles/d41... This new article analyses the pipeline of clinical-stage therapeutic cancer vaccines, including the technology platforms, antigen selection and personalization approaches

Tumour-agnostic kinase inhibitors nature.com/articles/s41... rdcu.be/fgiHN For readers interested in kinase inhibitors, this Review covers small-molecule inhibitors that target kinase pathway aberrations as tumour‐agnostic agents

Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies rdcu.be/fgg49 nature.com/articles/s41... This new Review covers the expanding toolkit for kinase modulation, such as allosteric modulators and molecular glues